Neoantigen targeted therapies market projected to reach USD 2.9 Billion by 2030, growing at an annualized rate of 57%, claims Roots Analysis

Published: June 2019


Roots Analysis has announced the addition of “Neoantigen Targeted Therapies, 2019-2030” report to its list of offerings. 

The use of neoantigens in therapy has demonstrated the ability to elicit a strong T cell mediated immune response. Several therapy candidates are being investigated both as monotherapies and in combination with various immune checkpoint inhibitors, such as atezolizumab, durvalumab, ipilimumab, and nivolumab. Of these, certain pipeline candidates have already entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years. 

The report presents opinions on several key aspects of the market. Among other elements, it includes:

Over 150+ candidate therapies in the development pipeline
Nearly 13% of the pipeline therapies are being developed for the treatment of GI cancers, followed by lung cancer (11%). Examples of molecules being developed for the aforementioned indications include (in alphabetical order, no specific selection criteria) MicOryx, NCI-4650, and Tedopi®.

1,100+ patents filed / granted in 2018 
In fact, more than 6,000 patents were filed / granted related to neoantigen targeted therapies, since 1978. Based on existing intellectual property, the R&D activity was observed to be concentrated in the US. Other key regions with significant intellectual capital include (in decreasing order of number of patents filed / granted) Australia, Europe, China, and Canada.

Close to USD 7.5 billion invested by both private and public investors, since 2014
Around USD 3,200 million was raised through venture capital financing, representing around 43% of the total capital raised by industry players in the given time period (till April 2019). Further, in the last five years, there have been 10 IPOs accounting for more than 800 million in financing of neoantigen related initiatives.

Companies are collaborating actively for the advancement of clinical trials
Majority of the abovementioned agreements were observed to be focused on conducting Phase I / Phase II clinical studies of neoantigen targeted therapies for the treatment of different cancer indications. Agreements signed for research purposes (19%) were also observed to be popular among industry stakeholders, during 2014-2019 (till April). 

More than 350 publications have been published since 2014
It is worth noting that between the period 2014-2019, over 150 research articles were published related to neoantigen targeted therapies. Further, more than 190 review articles have been published related to this upcoming field.  

Therapies using personalized neoantigens are anticipated to increase at a CAGR of over 60% between 2024 and 2030
This growth is anticipated to be primarily driven by the reduced risk of adverse effects and improved efficacy of personalized therapies. North America (primarily the US) and Europe are expected to capture the majority share by 2030, in terms of the sales-based revenues.

The USD 3 billion (by 2030) financial opportunity within the neoantigens market has been analyzed across the following segments:

  • Type of target disease indication
    • Bone cancer
    • Colorectal cancer
    • Gynecological cancer
    • Non-small cell lung cancer
    • Renal cell carcinoma
    • Other cancers
  • Type of neoantigens 
    • Personalized neoantigens
    • Off-the-shelf neoantigens
  • Type of immunotherapy
    • Dendritic cell vaccines
    • DNA / RNA-based vaccines
    • Protein / peptide-based vaccines
    • TIL-based therapies
  • Route of administration 
    • Intradermal
    • Intravenous
    • Subcutaneous
    • Other routes
  • Key geographical regions 
    • North America
    • Europe
    • Rest of the World

The report features inputs from eminent industry stakeholders, according to whom neoantigen targeted therapies are expected to be the next big step in cancer immunotherapy. Similar to CAR-T cell therapies, these therapies have, so far, demonstrated significant therapeutic potential and promising clinical outcomes. The report includes detailed transcripts of discussions held with the following experts:

  • Gabriel Nistor (Chief Science Officer, AIVITA Biomedical)
  • Ella Sorani (Vice President Research and Development, BioLineRx)
  • Heinz Lubenau (Chief Operating Officer & Co-founder, VAXIMM)

The research covers detailed profiles, featuring an overview of the company, its financial information (if available), and a description of its product(s), highlighting type of therapy, current development status, and key preclinical / clinical trial results. Each profile also includes a list of recent developments, and an informed opinion on the likely strategies that may be adopted by these players to fuel growth in the foreseen future. 

  • Bavarian Nordic
  • Genocea Biosciences
  • Gradalis
  • Immunicum
  • Immunovative Therapies
  • Iovance Biotherapeutics
  • Medigene
  • Neon Therapeutics
  • Precision Biologics
  • Vaxon Biotech

For additional details, please visit 
https://rootsanalysis.com/reports/view_document/cell-encapsulation-focus-on-therapeutics-and-technologies-2019-2030/249.html
or email sales@rootsanalysis.com 

Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry